Scientist I/II, Modality Engineering
Required skills
- oligonucleotides
- bioconjugates
- AAV therapeutics
- ASOs
- siRNAs
- automated solid-phase synthesis
- chromatography
- mass spectrometry
- ASO/siRNA therapeutic chemistry
- backbone and sugar modifications
Nice to have
- small biotech
- AAV biology
- vector design
- AAV capsid engineering
- pooled library design
- NGS data analysis
Role summary
Lexeo is seeking a Scientist I/II in Modality Engineering to design, synthesize, and characterize oligonucleotides, bioconjugates, and AAV therapeutics. This hands-on role involves advancing molecules from design through analytical characterization, collaborating with chemistry, molecular biology, and pharmacology teams. Responsibilities include managing CROs, optimizing conjugation chemistry, developing analytical methods, engineering AAV vectors, and supporting molecule advancement. The position requires a PhD or MS with relevant industry experience and offers broad exposure to multidisciplinary biopharma research for genetic heart disease therapies.
Role Summary
Lexeo is hiring a hands-on Modality Engineering Scientist to design, synthesize, and characterize oligonucleotides, bioconjugates, and AAV therapeutics for our discovery pipeline. The scientist will advance molecules from design through analytical characterization and handoff to in vitro and in vivo teams, working across chemistry, molecular biology, and pharmacology. Reporting to the Head of Cardiac Research, this role joins cardiac, neuroscience, and non-clinical scientists developing therapies for genetic heart disease and offers broad experience in multidisciplinary biopharma research.
Primary Responsibilities
Required Skills and Qualifications
Preferred Skills and Qualifications
About LEXEO
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
LEXEO Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.
Similar roles
- Scientist II, Cellular Neuroscience and Translational PharmacologyLexeo Therapeutics · New York, NY · Onsite
- Manager/Senior Manager, CMC Quality ControlLexeo Therapeutics · New York, NY · Hybrid
Clinical Lab Scientist ICareDx, Inc. · Brisbane, CA · Onsite- Machine Learning Scientist II, Drug Discovery AnalyticsRevolution Medicines · Redwood City, CA · Hybrid
Principal Decision Scientist, Client AnalyticsIbotta · Denver, CO · Hybrid- Data Scientist, PreparednessOpenAI · Remote · Remote
